- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Patent License Agreement
A patent license agreement is an arranged understanding between a patent holder and a licensee. When the parties have arranged the particulars of an understanding, the parties enter into an agreement where the patent holder (licensor) consents to permit the licensee to utilize, make, sell, or import the protected development to the US in return … Continue reading Patent License Agreement
Read more »Export Of Patented Product For Research Or Experimental Purposes– A Part Of Bolar Exemption
The High Court of Delhi had finally adjudged, the case of Bayer Corporation v. Union of India & Ors and Bayer Intellectual Property gmbh & Anr, v. Alembic Pharmaceutical Limited by the order dated 22.04.2019, on the scope of section107(A) of Indian Patent Act 1970 by reading the meaning of word ‘export’ into it, though … Continue reading Export Of Patented Product For Research Or Experimental Purposes– A Part Of Bolar Exemption
Read more »First Compulsory License Grant in India to Natco
March 31, 2012 - 1:58 pm
Categories:
IP Practice in India
News & Updates
Pharma/Biotech Patent Litigations
1 Comments The Controller General of India passed an order of compulsory license (CL) against Bayer’s patent on drug Nexavar on March 09, 2012, which is India’s first compulsory license and is resulting from India’s first CL application filed by Natco last year which was reported and discussed by us here. The grant permits the Nacto to … Continue reading First Compulsory License Grant in India to Natco
Read more »Natco Files India’s First Compulsory Licensing Application
September 14, 2011 - 4:38 am
Categories:
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be … Continue reading Natco Files India’s First Compulsory Licensing Application
Read more »Bayer Vs Cipla
BAYER Vs CIPLA & UNION OF INDIA Does a combined reading of the Drug Control Act and the Patents Act lead to an inference that no marketing approvals can be granted to a third party for a drug/formulation for which a patent exists? This was a primary question before the Delhi High Court in a … Continue reading Bayer Vs Cipla
Read more »